What Is Selank? Mechanism, Uses, Risks, and FDA Status
What Is Selank?
Selank (TP-7) is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is based on the naturally occurring immunomodulatory peptide tuftsin (Thr-Lys-Pro-Arg), with an additional Gly-Pro sequence added to improve metabolic stability. Selank was approved in Russia in 2009 as an anxiolytic and nootropic medication, administered as a nasal spray. It is classified as a "peptide anxiolytic" that combines anti-anxiety effects with cognitive enhancement without the sedation, dependence, or withdrawal associated with benzodiazepines.
How Does Selank Work?
Selank modulates multiple neurotransmitter systems and neurotrophic pathways:
- GABA system modulation — Research suggests Selank allosterically modulates GABA-A receptors, enhancing inhibitory neurotransmission without directly binding the benzodiazepine site (Seredenin et al., Bull Exp Biol Med, 2008)
- Serotonin metabolism — Selank influences serotonin metabolism by inhibiting enkephalinase, which affects the balance of monoamine neurotransmitters
- BDNF upregulation — Animal studies show increased expression of brain-derived neurotrophic factor, which supports neuroplasticity and memory formation (Inozemtseva et al., Bull Exp Biol Med, 2008)
- Enkephalin stabilization — By inhibiting enzymes that degrade enkephalins, Selank may prolong the activity of endogenous opioid peptides involved in mood regulation
- IL-6 modulation — Selank influences interleukin-6 expression in the brain, connecting its anxiolytic effects to neuroimmune regulation
- Gene expression changes — Microarray studies reveal Selank affects expression of 36 genes related to neurotransmission, inflammation, and cellular stress responses
This multi-target mechanism distinguishes Selank from single-target anxiolytics and may explain its combined anxiolytic-nootropic profile.
What Is Selank Used For?
Based on published research and its approved indication in Russia:
- Generalized anxiety disorder — Approved in Russia for anxiety treatment; clinical studies showed efficacy comparable to medazepam (a benzodiazepine) without sedation or dependence (Zozulya et al., Bull Exp Biol Med, 2008)
- Cognitive enhancement — Research suggests improved memory consolidation, attention, and learning in both animal models and human studies
- Neurasthenia and adjustment disorders — Part of the approved Russian indication for stress-related cognitive and emotional symptoms
- Immune modulation — Derived from tuftsin, Selank retains immunomodulatory properties including enhanced phagocyte activity and cytokine regulation
- Depression (adjunctive) — Preliminary research into augmenting antidepressant therapy, particularly for anxiety-predominant presentations
- ADHD-related symptoms — Early-stage research into attention and executive function enhancement
What Are the Risks and Side Effects?
- Limited Western clinical data — While approved in Russia, Selank has not undergone FDA-supervised clinical trials; most published research is from Russian institutions
- Mild and transient side effects — Russian clinical data reports a favorable safety profile with minimal adverse events; the most common are nasal irritation (intranasal route) and mild fatigue
- Unknown long-term effects — Chronic use data beyond the studied periods (typically 14–28 days) is limited
- Potential interactions — May interact with benzodiazepines, SSRIs, or other CNS-active medications through overlapping mechanisms
- Regulatory uncertainty — Not approved outside Russia; quality and authenticity of non-pharmaceutical sources cannot be guaranteed
- Immunomodulatory effects — The tuftsin-derived immune effects could theoretically be problematic in autoimmune conditions, though this has not been demonstrated
- Nasal mucosa effects — Long-term intranasal administration effects on nasal tissue are not well characterized
FDA Status
Selank is classified as unregulated in the United States — it has no FDA approval and has not undergone FDA-supervised clinical trials. It is approved in Russia as a prescription anxiolytic/nootropic. In the US, it is available as a research compound and through some compounding pharmacies. Selank is pending PCAC review (Pharmacy Compounding Advisory Committee) scheduled for July 2026, which may affect its availability through compounding pathways. For the latest regulatory updates, visit our FDA tracker.
Key Studies and Evidence Base
| Study | Finding | |-------|---------| | Zozulya et al., 2008 (Bull Exp Biol Med) | Clinical trial: Selank showed anxiolytic efficacy comparable to medazepam without sedation or dependence in GAD patients | | Seredenin et al., 2008 | Selank modulates GABA-A receptor function and monoamine metabolism in anxiety models | | Inozemtseva et al., 2008 | Selank increased BDNF mRNA expression in rat hippocampus, correlating with improved memory | | Kozlovskii & Danchev, 2003 | Selank enhanced cognitive performance in passive avoidance and Morris water maze tests | | Uchakina et al., 2008 | Immunomodulatory effects: Selank influenced cytokine expression and immune cell function |
The Bottom Line
Selank is a well-characterized anxiolytic peptide with a unique multi-target mechanism that combines anti-anxiety effects with cognitive enhancement — without the sedation or dependence risk of benzodiazepines. Its approval in Russia and favorable safety profile in clinical studies are encouraging, but the lack of FDA-supervised trials and limited independent Western replication mean the evidence should be interpreted cautiously. Its pending PCAC review in July 2026 adds regulatory uncertainty for US availability. Anyone considering Selank should consult a healthcare provider, particularly if taking other CNS-active medications.
This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy. TruPeptide does not sell peptides or facilitate purchases.